XSWX
SHLTN
Market cap48mUSD
Sep 17, Last price
1.07CHF
1D
4.90%
1Q
17.58%
Jan 2017
-84.38%
IPO
-97.63%
Name
SHL Telemedicine Ltd
Chart & performance
P/E
—
P/S
0.85
EPS
—
Div yield, %
—
Shrs. gr., 5y
9.31%
Rev. gr., 5y
6.27%
Revenues
57m
-0.52%
Net income
-28m
L+298.17%
CFO
-372k
L-75.13%
Dividend
Apr 10, 20191 CHF/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1987 and headquartered in Tel Aviv, Israel, SHL Telemedicine Ltd. is a global provider specializing in the development and distribution of individual remote healthcare solutions across Israel, Europe, and other international markets. The company's extensive product line includes a variety of advanced electrocardiogram (ECG) devices designed for personal use: Smartheart, a mobile 12-lead ECG capable of identifying heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter; Cardio'B, a portable 12-lead ECG unit; and the Cardio Beeper 12/12, a handheld device that transmits full ECG readings to a monitoring center. Beyond cardiac monitoring, SHL offers a suite of other remote diagnostic tools, such as a central communication module for relaying medical data from various devices to its telemedicine centers, TeleWeight for trans-telephonic weight tracking, TelePress for remote blood pressure measurements, TeleBreather for assessing lung function, and the TelePulse Oximeter for measuring blood oxygen saturation and pulse rate. These telemedicine services and devices are delivered to subscribers via both telephonic and internet communication channels. The company caters to a diverse range of clients, including individual patients, health insurance providers, hospitals, clinics, medical practitioners, and other healthcare organizations. SHL Telemedicine is also engaged in key collaborative research efforts. It partners with the Mayo Clinic to evaluate the efficacy of its FDA-approved SmartHeart in reducing emergency department visits, re-hospitalizations, and major adverse cardiovascular events in post-heart attack patients over a 90-day period. Additionally, the company is working with the Hebrew University of Jerusalem and the Hadassah Medical Center to create an artificial intelligence tool designed to predict future life-threatening cardiac incidents based on 12-Lead ECG monitoring.
Key people
Yoav Rubinstein
Chief Executive Officer, Senior Vice President, Vice President - Business Development · since 2017
Yossi Vadnagra
Chief Financial Officer · since 2017
Yoni Dagan
Chief Technology Officer · since 2017
Ralf Bork
Interim Acting Managing Director of SHL Germany · since 2019
Arie Roth
Chief Medical Manager
Yehoshua Abramovich
Board of Director · since 2017
Yoram Alroy
President, Non-Executive Director · since 2011
Non-Executive Director · since 2016
Yi He
Non-Executive Director · since 2017
Dvora Kimhi
Non-Executive Director · since 2010
Amir Lerman
Non-Executive Director · since 2016
Cailong Su
Non-Executive Director · since 2017
Shenlu Xu
Non-Executive Director · since 2017
Independent Non-Executive Director · since 2007
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||